$22.69 -$0.30 (-1.3%)

03:38 PM EDT on 06/19/19

Editas Medicine (NASDAQ:EDIT)

CAPS Rating: 4 out of 5

Current Price $22.69 Mkt Cap $1.1B
Open $23.09 P/E Ratio 0.00
Prev. Close $22.99 Div. (Yield) $0.00 (0.0%)
Daily Range $22.67 - $23.20 Volume 79,711
52-Wk Range $19.01 - $28.15 Avg. Daily Vol. 16


How do you think NASDAQ:EDIT will perform against the market?

Add Stock to CAPS Watchlist

All Players

233 Outperform
9 Underperform

All-Star Players

96 Outperform
2 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:EDIT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

rhallbick (90.50)
Submitted April 15, 2018

Editas Medicine (NASDAQ: EDIT) is a biotech specializing in CRISPR-Cas9 research and development. CRISPR has promise for the treatment of patients with genetically defined diseases by correcting their disease?causing genes.CRISPR is an acronym for… More

btechrisk11 (< 20)
Submitted April 15, 2018

Still a lot to learn for CRISPR technology to translate to clinic safely. CRISPR can be fairly selective but there was a recent journal article suggesting many people have antibodies/immune responses against some of the CRISPR elements.



Fools bullish on NASDAQ:EDIT are also bullish on:

Fools bearish on NASDAQ:EDIT are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about EDIT.


Member Avatar WilliamEbonics (67.22) Submitted: 5/20/2019 5:28:14 PM : Underperform Start Price: $22.17 NASDAQ:EDIT Score: +0.23

The Stock continues a downward drift, while money also continues to exit the stock over an extended period of time.


Member Avatar MarkFitzFool (45.92) Submitted: 5/11/2019 3:08:22 PM : Outperform Start Price: $24.45 NASDAQ:EDIT Score: -11.01

It's been a bumpy ride for Editas over the past few years, but such is the nature of being a developmental stage biotech company. What sets Editas apart is their leadership. Feng Zhang, one of the developers of both CRISPR and optogenetics, is a co-founder, as is George Church, one of the most famous scientists in the world and a pioneer of both synthetic biology and personalized genomics. Editas is early-stage, and inherently risky, but I'm extremely confident that they will prevail. They have a robust developmental and preclinical pipeline with therapies for Beta-Thalassemia, Sickle Cell, DMD, Cystic Fibrosis, genetic diseases of the eye and liver, CAR-T for cancer therapy, etc. Will they be the first to market with one of their cutting-edge non-CAR-T gene-editing therapies? Likely not (I think bluebird bio will beat them), but they have many promising shots on goal that position them to be a leader in the space. Furthermore, The Broad Institute holds several CRISPR patents, and both Zhang and Church are members of said institute. I foresee Editas being one the future's top companies for personalized genetic therapies.


Member Avatar LastPlaceLenny (53.70) Submitted: 3/15/2019 3:26:17 AM : Underperform Start Price: $24.03 NASDAQ:EDIT Score: +10.09

Not ready to take off yet, will out perform in long run, but not sure when that long run starts. Not this year.


Find the members with the highest scoring picks in EDIT.

Score Leader


PAGEBOY73 (99.03) Score: +120.59

The Score Leader is the player with the highest score across all their picks in EDIT.

Member Name Member
Call Time
Score Commentary
SeriousK 29.04 3/9/2016 Underperform 5Y $42.70 -46.86% +47.07% +93.93 0 Comment
TimeToBuy 86.77 3/10/2016 Underperform 5Y $32.50 -30.18% +46.62% +76.81 0 Comment
nobody2013 < 20 3/10/2016 Underperform NS $26.79 -15.30% +47.87% +63.18 1 Comment
willism 35.52 1/29/2018 Underperform 3Y $40.64 -44.17% +2.59% +46.76 0 Comment
btechrisk11 < 20 4/16/2018 Underperform 3Y $34.93 -35.04% +9.81% +44.85 1 Comment
freemarketmike < 20 6/7/2017 Outperform 5Y $15.43 +47.02% +20.39% +26.64 1 Comment
CMFMLove 39.79 6/13/2017 Outperform 5Y $16.00 +41.81% +20.17% +21.64 1 Comment
Playa14 < 20 6/9/2017 Outperform 5Y $16.08 +41.11% +20.12% +20.99 0 Comment
WoollyWombat < 20 9/16/2016 Outperform 5Y $14.48 +56.70% +37.42% +19.28 0 Comment
FunesDMemorious 97.95 10/26/2016 Outperform 5Y $14.55 +55.95% +37.51% +18.43 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EDIT.